{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:13:07Z","timestamp":1793743987369,"version":"4.6.1"},"reference-count":93,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Streptococcus pneumoniae remains the leading cause of community-acquired pneumonia in adults and bacterial meningitis in children worldwide. In addition to pneumonia, invasive pneumococcal diseases (IPDs), such as bacteremia and meningitis, pose a significant burden, particularly among older adults and individuals with underlying comorbidities. These diseases lead to substantial morbidity and mortality. Pneumococcal vaccination has been a cornerstone of disease prevention, reducing incidence and antimicrobial resistance. Recent advances in understanding S. pneumoniae epidemiology, genomic diversity, and the real-world impact of conjugate vaccines have driven the development and licensure of new-generation pneumococcal vaccines with expanded serotype coverage. Introducing 15-valent (PCV15), 20-valent (PCV20), and 21-valent (PCV21) conjugate vaccines has reshaped pneumococcal immunization strategies, particularly in adults, replacing previous sequential vaccine recommendations in many settings. In parallel, emerging epidemiological data and shifts in pneumococcal serotype distribution continue to influence vaccine policy decisions and immunization guidelines worldwide. In light of these advancements, adult pneumococcal vaccination recommendations continuously evolve to enhance protection in high-risk populations and optimize long-term immunity. This review provides an updated overview of the pneumococcal disease burden, the evolution of pneumococcal vaccines, and the latest immunization strategies in an expanding vaccine landscape. Additionally, we discuss future directions in pneumococcal vaccine development and the potential impact of novel vaccination approaches on public health outcomes.<\/jats:p>","DOI":"10.3390\/vaccines13050498","type":"journal-article","created":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T08:20:53Z","timestamp":1746606053000},"page":"498","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["The New Era of Pneumococcal Vaccination in Adults: What Is Next?"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3494-8997","authenticated-orcid":false,"given":"Lale","family":"Ozisik","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, Hacettepe University, Ankara 06100, T\u00fcrkiye"},{"name":"Department of Vaccinology, Vaccine Institute, Hacettepe University, Ankara 06100, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1586\/erv.12.53","article-title":"The fundamental link between pneumococcal carriage and disease","volume":"11","author":"Simell","year":"2012","journal-title":"Expert. Rev. Vaccines"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3201\/eid0805.010235","article-title":"Nasopharyngeal carriage of Streptococcus pneumoniae in healthy children: Implications for the use of heptavalent pneumococcal conjugate vaccine","volume":"8","author":"Marchisio","year":"2002","journal-title":"Emerg. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.jinf.2020.07.035","article-title":"Streptococcus pneumoniae serotype distribution and antimicrobial nonsusceptibility trends among adults with pneumonia in the United States, 2009\u20132017","volume":"81","author":"Suaya","year":"2020","journal-title":"J. Infect."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa1408544","article-title":"Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults","volume":"372","author":"Bonten","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Luck, J.N., Tettelin, H., and Orihuela, C.J. (2020). Sugar-Coated Killer: Serotype 3 Pneumococcal Disease. Front. Cell Infect. Microbiol., 10.","DOI":"10.3389\/fcimb.2020.613287"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1469-0691.2010.03183.x","article-title":"Streptococcus pneumoniae: Virulence factors and variation","volume":"16","author":"Mitchell","year":"2010","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/s41579-018-0001-8","article-title":"Streptococcus pneumoniae: Transmission, colonization and invasion","volume":"16","author":"Weiser","year":"2018","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Gergova, R., Boyanov, V., Muhtarova, A., and Alexandrova, A. (2024). A Review of the Impact of Streptococcal Infections and Antimicrobial Resistance on Human Health. Antibiotics, 13.","DOI":"10.3390\/antibiotics13040360"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Aceil, J., and Avci, F.Y. (2022). Pneumococcal Surface Proteins as Virulence Factors, Immunogens, and Conserved Vaccine Targets. Front. Cell Infect. Microbiol., 12.","DOI":"10.3389\/fcimb.2022.832254"},{"key":"ref_10","unstructured":"WHO (2017). Ranking of Other Drug-Resistant Bacterial Infections. Prioritization of Pathogens to Guide Discovery, Research and Development of New Antibiotics for Drug-Resistant Bacterial Infections, Including Tuberculosis, WHO."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"107072","DOI":"10.1016\/j.ijantimicag.2023.107072","article-title":"Global trends in non-susceptibility rates of Streptococcus pneumoniae isolates to ceftriaxone: Data from the antimicrobial testing leadership and surveillance (ATLAS) programme, 2016\u20132021","volume":"63","author":"Wang","year":"2024","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.chembiol.2023.11.003","article-title":"Convergent impact of vaccination and antibiotic pressures on pneumococcal populations","volume":"31","author":"Johnson","year":"2024","journal-title":"Cell Chem. Biol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S1473-3099(19)30297-X","article-title":"Pneumococcal lineages associated with serotype replacement and antibiotic resistance in childhood invasive pneumococcal disease in the post-PCV13 era: An international whole-genome sequencing study","volume":"19","author":"Lo","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa0800836","article-title":"Effect of pneumococcal conjugate vaccine on pneumococcal meningitis","volume":"360","author":"Hsu","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3201\/eid2402.171268","article-title":"Spread of Meropenem-Resistant Streptococcus pneumoniae Serotype 15A-ST63 Clone in Japan, 2012\u20132014","volume":"24","author":"Nakano","year":"2018","journal-title":"Emerg. Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3343\/alm.2023.43.1.45","article-title":"Serotype Distribution and Antimicrobial Resistance of Streptococcus pneumoniae Causing Invasive Pneumococcal Disease in Korea Between 2017 and 2019 After Introduction of the 13-Valent Pneumococcal Conjugate Vaccine","volume":"43","author":"Kim","year":"2023","journal-title":"Ann. Lab. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1080\/22221751.2021.2000892","article-title":"Re-emergence of invasive pneumococcal disease (IPD) and increase of serotype 23B after easing of COVID-19 measures, Switzerland, 2021","volume":"10","author":"Casanova","year":"2021","journal-title":"Emerg. Microbes Infect."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1128\/JCM.01778-16","article-title":"Emergence of Multidrug-Resistant Pneumococcal Serotype 35B among Children in the United States","volume":"55","author":"Olarte","year":"2017","journal-title":"J. Clin. Microbiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/S1473-3099(18)30310-4","article-title":"Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990\u20132016: A systematic analysis for the Global Burden of Disease Study 2016","volume":"18","author":"Collaborators","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref_20","unstructured":"(2025, April 17). World Health Statistics 2024: Monitoring Health for the SDGs, Sustainable Development Goals; Geneva: World Health Organization; 2024. Licence: CC BY-NC-SA 3.0 IGO. Available online: https:\/\/iris.who.int\/bitstream\/handle\/10665\/376869\/9789240094703-eng.pdf."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/resp.14389","article-title":"Trends of global and regional aetiologies, risk factors and mortality of lower respiratory infections from 1990 to 2019: An analysis for the Global Burden of Disease Study 2019","volume":"28","author":"Kang","year":"2023","journal-title":"Respirology"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Safiri, S., Mahmoodpoor, A., Kolahi, A.A., Nejadghaderi, S.A., Sullman, M.J.M., Mansournia, M.A., Ansarin, K., Collins, G.S., Kaufman, J.S., and Abdollahi, M. (2022). Global burden of lower respiratory infections during the last three decades. Front. Public. Health, 10.","DOI":"10.3389\/fpubh.2022.1028525"},{"key":"ref_23","unstructured":"GBD 2021 Lower Respiratory Infections and Antimicrobial Resistance Collaborators (2024). Global, regional, and national incidence and mortality burden of non-COVID-19 lower respiratory infections and aetiologies, 1990\u20132021: A systematic analysis from the Global Burden of Disease Study 2021. Lancet Infect. Dis., 24, 974\u20131002."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"S570","DOI":"10.1093\/infdis\/jiz053","article-title":"Global and Regional Burden of Hospital Admissions for Pneumonia in Older Adults: A Systematic Review and Meta-Analysis","volume":"222","author":"Shi","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref_25","unstructured":"Centers for Disease Control and Prevention (2025, February 17). Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Streptococcus pneumoniae, 2019, Available online: www.cdc.gov\/abcs\/downloads\/SPN_Surveillance_Report_2019.pdf."},{"key":"ref_26","unstructured":"Centers for Disease Control and Prevention (2025, February 17). Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Streptococcus pneumoniae, 2022, Available online: https:\/\/www.cdc.gov\/abcs\/downloads\/SPN_Surveillance_Report_2022.pdf."},{"key":"ref_27","unstructured":"European Centre for Disease Prevention and Control (2022). Invasive Pneumococcal Disease\u2014Annual Epidemiological Report for 2022, European Centre for Disease Prevention and Control."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Bar-Zeev, N., Mtunthama, N., Gordon, S.B., Mwafulirwa, G., and French, N. (2015). Minimum incidence of adult invasive pneumococcal disease in Blantyre, Malawi an urban African setting: A hospital based prospective cohort study. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0128738"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1136\/thoraxjnl-2011-201092","article-title":"Serotype prevalence in adults hospitalised with pneumococcal non-invasive community-acquired pneumonia","volume":"67","author":"Bewick","year":"2012","journal-title":"Thorax"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.mm7401a1","article-title":"Expanded Recommendations for Use of Pneumococcal Conjugate Vaccines Among Adults Aged \u226550 Years: Recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2024","volume":"74","author":"Kobayashi","year":"2025","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/jama.285.13.1729","article-title":"Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995\u20131998: Opportunities for prevention in the conjugate vaccine era","volume":"285","author":"Robinson","year":"2001","journal-title":"JAMA"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1086\/516521","article-title":"Persistence of antibodies to pneumococcal capsular polysaccharide vaccine in the elderly","volume":"176","author":"Sankilampi","year":"1997","journal-title":"J. Infect. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0065-3101(24)00217-2","article-title":"Human immune responses to polysaccharide antigens: An analysis of bacterial polysaccharide vaccines in infants","volume":"32","author":"Barrett","year":"1985","journal-title":"Adv. Pediatr."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/00006454-200003000-00003","article-title":"Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group","volume":"19","author":"Black","year":"2000","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"4760","DOI":"10.1128\/iai.61.11.4760-4766.1993","article-title":"Stimulation of protective antibodies against type Ia and Ib group B streptococci by a type Ia polysaccharide-tetanus toxoid conjugate vaccine","volume":"61","author":"Wessels","year":"1993","journal-title":"Infect. Immun."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.2174\/15680266113136660180","article-title":"Novel strategies for development of next-generation glycoconjugate vaccines","volume":"13","author":"Avci","year":"2013","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nri2508","article-title":"B-cell responses to vaccination at the extremes of age","volume":"9","author":"Siegrist","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa022823","article-title":"Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine","volume":"348","author":"Whitney","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1586\/erv.09.113","article-title":"10-valent pneumococcal nontypeable Haemophilus influenzae PD conjugate vaccine: Synflorix","volume":"8","author":"Prymula","year":"2009","journal-title":"Expert. Rev. Vaccines"},{"key":"ref_40","unstructured":"Centers for Disease Control and Prevention (2010). Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children\u2014Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb. Mortal. Wkly. Rep., 59, 258\u2013261."},{"key":"ref_41","unstructured":"Centers for Disease Control and Prevention (2012). Licensure of 13-valent pneumococcal conjugate vaccine for adults aged 50 years and older. MMWR Morb. Mortal. Wkly. Rep., 61, 394\u2013395."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.15585\/mmwr.mm6846a5","article-title":"Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged \u226565 Years: Updated Recommendations of the Advisory Committee on Immunization Practices","volume":"68","author":"Matanock","year":"2019","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_43","first-page":"822","article-title":"Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged \u226565 years: Recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"63","author":"Tomczyk","year":"2014","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3201\/eid2801.210734","article-title":"Serotype Replacement after Introduction of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines in 10 Countries, Europe","volume":"28","author":"Hanquet","year":"2022","journal-title":"Emerg. Infect. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.vaccine.2021.08.049","article-title":"A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE)","volume":"40","author":"Platt","year":"2022","journal-title":"Vaccine"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"5428","DOI":"10.1016\/j.vaccine.2021.07.004","article-title":"A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults 18 through 49 years of age","volume":"39","author":"Klein","year":"2021","journal-title":"Vaccine"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"793","DOI":"10.15585\/mmwr.mm7336a3","article-title":"Use of 21-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2024","volume":"73","author":"Kobayashi","year":"2024","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/S0140-6736(10)62225-8","article-title":"Serotype replacement in disease after pneumococcal vaccination","volume":"378","author":"Weinberger","year":"2011","journal-title":"Lancet"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Teixeira, R., Kossyvaki, V., Galvez, P., and Mendez, C. (2023). Pneumococcal Serotype Evolution and Burden in European Adults in the Last Decade: A Systematic Review. Microorganisms, 11.","DOI":"10.3390\/microorganisms11061376"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"60.e9","DOI":"10.1016\/j.cmi.2015.08.027","article-title":"Strain features and distributions in pneumococci from children with invasive disease before and after 13-valent conjugate vaccine implementation in the USA","volume":"22","author":"Metcalf","year":"2016","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1080\/21645515.2015.1091908","article-title":"Interactions of conjugate vaccines and co-administered vaccines","volume":"12","author":"Findlow","year":"2016","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/s41541-023-00715-w","article-title":"Emerging vaccine strategies against the incessant pneumococcal disease","volume":"8","author":"Duke","year":"2023","journal-title":"NPJ Vaccines"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"ofae220","DOI":"10.1093\/ofid\/ofae220","article-title":"Immunogenicity of Current and Next-Generation Pneumococcal Conjugate Vaccines in Children: Current Challenges and Upcoming Opportunities","volume":"11","author":"Feemster","year":"2024","journal-title":"Open Forum Infect. Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"5513","DOI":"10.1016\/j.vaccine.2010.06.026","article-title":"Glycoconjugate vaccines and immune interference: A review","volume":"28","author":"Dagan","year":"2010","journal-title":"Vaccine"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"4946","DOI":"10.1128\/IAI.70.9.4946-4954.2002","article-title":"Effect of vaccination with carrier protein on response to meningococcal C conjugate vaccines and value of different immunoassays as predictors of protection","volume":"70","author":"Burrage","year":"2002","journal-title":"Infect. Immun."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.resinv.2024.12.007","article-title":"Pneumococcal vaccines for prevention of adult pneumonia","volume":"63","author":"Morimoto","year":"2025","journal-title":"Respir. Investig."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2460274","DOI":"10.1080\/21645515.2025.2460274","article-title":"Pneumococcal vaccines in China","volume":"21","author":"Wang","year":"2025","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_58","unstructured":"World Health Organization (2021). Considerations for Pneumococcal Conjugate Vaccine (PCV) Product Choice, World Health Organization."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1473-3099(22)00734-4","article-title":"Immunogenicity and safety of a 10-valent pneumococcal conjugate vaccine administered as a 2 + 1 schedule to healthy infants in The Gambia: A single-centre, double-blind, active-controlled, randomised, phase 3 trial","volume":"23","author":"Adigweme","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1016\/j.vaccine.2022.05.079","article-title":"Phase 1\/2 study of a novel 24-valent pneumococcal vaccine in healthy adults aged 18 to 64 years and in older adults aged 65 to 85 years","volume":"40","author":"Chichili","year":"2022","journal-title":"Vaccine"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S1473-3099(23)00572-8","article-title":"Evaluating the safety, tolerability, and immunogenicity of a 24-valent pneumococcal conjugate vaccine (VAX-24) in healthy adults aged 18 to 64 years: A phase 1\/2, double-masked, dose-finding, active-controlled, randomised clinical trial","volume":"24","author":"Wassil","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"126124","DOI":"10.1016\/j.vaccine.2024.07.025","article-title":"A phase 2, randomized, blinded, dose-finding, controlled clinical trial to evaluate the safety, tolerability, and immunogenicity of a 24-valent pneumococcal conjugate vaccine (VAX-24) in healthy adults 65 years and older","volume":"42","author":"Wassil","year":"2024","journal-title":"Vaccine"},{"key":"ref_63","unstructured":"(2025, March 25). Safety, Tolerability, and Immunogenicity Study of a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in Adults, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06151288."},{"key":"ref_64","unstructured":"(2025, March 25). Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06077656?cond=25valent%20pneumococcal%20conjugate&rank=2."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2117949","DOI":"10.1080\/21645515.2022.2117949","article-title":"Multi-valent pneumococcal conjugate vaccine for global health: From problem to platform to production","volume":"18","author":"Datta","year":"2022","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/s41467-019-08869-9","article-title":"A platform for glycoengineering a polyvalent pneumococcal bioconjugate vaccine using E. coli as a host","volume":"10","author":"Harding","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Lagousi, T., Basdeki, P., Routsias, J., and Spoulou, V. (2019). Novel Protein-Based Pneumococcal Vaccines: Assessing the Use of Distinct Protein Fragments Instead of Full-Length Proteins as Vaccine Antigens. Vaccines, 7.","DOI":"10.3390\/vaccines7010009"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Oliveira, G.S., Oliveira, M.L.S., Miyaji, E.N., and Rodrigues, T.C. (2021). Pneumococcal Vaccines: Past Findings, Present Work, and Future Strategies. Vaccines, 9.","DOI":"10.3390\/vaccines9111338"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"4255","DOI":"10.1016\/j.vaccine.2018.05.122","article-title":"Immunogenicity and mechanisms of action of PnuBioVax, a multi-antigen serotype-independent prophylactic vaccine against infection with Streptococcus pneumoniae","volume":"36","author":"Hill","year":"2018","journal-title":"Vaccine"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"4610","DOI":"10.1016\/j.vaccine.2015.06.078","article-title":"Safety and immunogenicity of a trivalent recombinant PcpA, PhtD, and PlyD1 pneumococcal protein vaccine in adults, toddlers, and infants: A phase I randomized controlled study","volume":"33","author":"Brooks","year":"2015","journal-title":"Vaccine"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/s41541-024-01033-5","article-title":"Intranasal influenza-vectored vaccine expressing pneumococcal surface protein A protects against Influenza and Streptococcus pneumoniae infections","volume":"9","author":"Cardoso","year":"2024","journal-title":"NPJ Vaccines"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"David, S.C., Brazel, E.B., Singleton, E.V., Minhas, V., Laan, Z., Scougall, C., Chen, A.Y., Wang, H., Gates, C.J., and McLean, K.T. (2022). A Nonadjuvanted Whole-Inactivated Pneumococcal Vaccine Induces Multiserotype Opsonophagocytic Responses Mediated by Noncapsule-Specific Antibodies. mBio, 13.","DOI":"10.1128\/mbio.02367-22"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"4870","DOI":"10.1128\/IAI.69.8.4870-4873.2001","article-title":"Intranasal immunization with killed unencapsulated whole cells prevents colonization and invasive disease by capsulated pneumococci","volume":"69","author":"Malley","year":"2001","journal-title":"Infect. Immun."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"7468","DOI":"10.1016\/j.vaccine.2010.09.031","article-title":"GMP-grade pneumococcal whole-cell vaccine injected subcutaneously protects mice from nasopharyngeal colonization and fatal aspiration-sepsis","volume":"28","author":"Lu","year":"2010","journal-title":"Vaccine"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/INF.0000000000002567","article-title":"A Phase 1 Randomized, Placebo-controlled, Observer-blinded Trial to Evaluate the Safety and Immunogenicity of Inactivated Streptococcus pneumoniae Whole-cell Vaccine in Adults","volume":"39","author":"Keech","year":"2020","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Morais, V., Texeira, E., and Suarez, N. (2019). Next-Generation Whole-Cell Pneumococcal Vaccine. Vaccines, 7.","DOI":"10.3390\/vaccines7040151"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2469424","DOI":"10.1080\/21645515.2025.2469424","article-title":"Global distribution and characteristics of pneumococcal serotypes in adults","volume":"21","author":"Maeda","year":"2025","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1080\/14737167.2022.2134120","article-title":"Cost-effectiveness of using a 20-valent pneumococcal conjugate vaccine to directly protect adults in England at elevated risk of pneumococcal disease","volume":"22","author":"Mendes","year":"2022","journal-title":"Expert. Rev. Pharmacoecon Outcomes Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s40273-016-0439-3","article-title":"Cost Effectiveness of Pneumococcal Vaccination in Children in Low- and Middle-Income Countries: A Systematic Review","volume":"34","author":"Saokaew","year":"2016","journal-title":"Pharmacoeconomics"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Vo, N.X., Pham, H.L., Bui, U.M., Ho, H.T., and Bui, T.T. (2024). Cost-Effectiveness of the Pneumococcal Vaccine in the Adult Population: A Systematic Review. Healthcare, 12.","DOI":"10.20944\/preprints202408.0830.v1"},{"key":"ref_81","unstructured":"Centers for Disease Control and Prevention (2025, March 27). Vaccination Coverage Among Adults in the United States, National Health Interview Survey, 2016, Available online: https:\/\/www.cdc.gov\/adultvaxview\/publications-resources\/vaccination-coverage-adults-2016.html."},{"key":"ref_82","unstructured":"International Longevity Centre UK (2025, March 27). European Pneumococcal Vaccination: A Progress Report. Available online: https:\/\/ilcuk.org.uk\/wp-content\/uploads\/2023\/01\/ILC-European-Pneumococcal-Vaccination.pdf."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.4161\/hv.25826","article-title":"The effect of physicians\u2019 awareness on influenza and pneumococcal vaccination rates and correlates of vaccination in patients with diabetes in Turkey: An epidemiological Study \u201cdiaVAX\u201d","volume":"9","author":"Satman","year":"2013","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"441","DOI":"10.4161\/hv.7.4.14188","article-title":"Cost of pneumococcal infections and cost-effectiveness analysis of pneumococcal vaccination at risk adults and elderly in Turkey","volume":"7","author":"Akin","year":"2011","journal-title":"Hum. Vaccin."},{"key":"ref_85","unstructured":"(2025, March 27). ECDC Vaccine Scheduler: Pneumococcal Disease, Recommended vaccinations in European Countries. Available online: https:\/\/vaccine-schedule.ecdc.europa.eu\/Scheduler\/ByDisease?SelectedDiseaseId=25&SelectedCountryIdByDisease=-1."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"126390","DOI":"10.1016\/j.vaccine.2024.126390","article-title":"National recommendations for adult pneumococcal vaccination in countries of the WHO regions of Americas, Africa, Eastern Mediterranean, South East Asia, and Western Pacific","volume":"42","author":"Fletcher","year":"2024","journal-title":"Vaccine"},{"key":"ref_87","unstructured":"(2025, March 27). Ei\u015fkin Ba\u011f\u0131\u015f\u0131klama Rehberi-2024, T\u00fcrkiye Enfeksiyon Hastal\u0131klar\u0131 ve Klinik Mikrobiyoloji Uzmanl\u0131k Derne\u011fi. Available online: https:\/\/www.ekmud.org.tr\/files\/uploads\/files\/eriskin-bagisiklama-rehberi-2024.pdf."},{"key":"ref_88","unstructured":"World Health Organization (2021). Considerations for pneumococcal vaccination in older adults. Wkly. Epidemiol. Rec., 96, 217\u2013228."},{"key":"ref_89","unstructured":"(2025, April 21). Global Vaccine Action Plan 2011\u20132020. Geneva: World Health Organization. Available online: https:\/\/www.who.int\/publications\/i\/item\/global-vaccine-action-plan-2011-2020."},{"key":"ref_90","unstructured":"WHO (2025, April 20). Immunization Agenda 2030: A Global Strategy To Leave No One Behind. Available online: https:\/\/cdn.who.int\/media\/docs\/default-source\/immunization\/strategy\/ia2030\/ia2030-draft-4-wha_b8850379-1fce-4847-bfd1-5d2c9d9e32f8.pdf?sfvrsn=5389656e_69&download=true."},{"key":"ref_91","unstructured":"(2025, April 20). Gavi, the Vaccine Alliance, Strategy 2021\u20132025: Saving Lives and Protecting Livelihoods. Available online: https:\/\/www.gavi.org\/our-alliance\/strategy\/phase-5-2021-2025\/equity-goal."},{"key":"ref_92","unstructured":"World Health Organization (2024). Routine vaccination coverage\u2014Worldwide, 2023. Wkly. Epidemiol. Rec., 99, 641\u2013652."},{"key":"ref_93","unstructured":"(2025, April 20). WHO SAGE Values Framework. Available online: https:\/\/iris.who.int\/bitstream\/handle\/10665\/334299\/WHO-2019-nCoV-SAGE_Framework-Allocation_and_prioritization-2020.1-eng.pdf?sequence=1."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/5\/498\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:28:44Z","timestamp":1760030924000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/5\/498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,7]]},"references-count":93,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["vaccines13050498"],"URL":"https:\/\/doi.org\/10.3390\/vaccines13050498","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,7]]}}}